Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL), a Delaware corporation, filed this Current Report on Form 8-K on August 12, 2021. The filing primarily serves to announce the Company's financial results for the quarter ended June 30, 2021, via a press release furnished as Exhibit 99.1. The Company is classified as an emerging growth company.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the press release (Exhibit 99.1) referenced in Item 2.02 but are not included in the body of this 8-K filing.
Material Changes
No specific material changes in financial condition or operations are quantified in this document. The filing indicates that the Company has updated its corporate deck, available on its investor relations website, which may contain comparative data.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, and specific risk factors are contained within the press release (Exhibit 99.1) and the updated corporate deck. This 8-K filing includes a standard disclaimer stating that the information provided shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability for forward-looking statements unless expressly incorporated by reference in other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 12, 2021) for specific Q2 2021 financial figures.
- Access the updated corporate deck at the Company's investor relations website for detailed operational updates.
- Verify the Company's status as an emerging growth company and any associated election regarding extended transition periods for accounting standards.
- Confirm the trading symbol (DTIL) and exchange (Nasdaq Global Select Market) for the common stock.